Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Tricida, Inc. is a biotechnology company focused on developing therapies for patients with chronic kidney disease (CKD) and metabolic acidosis. Its lead product candidate, veverimer, targets the treatment of metabolic acidosis in CKD patients, which is a significant unmet medical need. The company operates primarily in the United States, with a focus on addressing the health challenges faced by this patient population.
Tricida generates revenue primarily through the commercialization of veverimer, which is designed to treat metabolic acidosis in CKD patients. The company has established a pricing strategy that reflects the value of its therapy in improving patient outcomes, leveraging its unique clinical data to negotiate favorable reimbursement terms.
FDA approval status of veverimer - critical for market entry
Clinical trial results and data releases - impact on perceived efficacy and safety
Partnerships or collaborations with larger pharmaceutical companies - can enhance distribution and marketing capabilities
Market adoption rates post-launch - critical for revenue generation
Regulatory changes impacting drug approval processes
Technological disruption in treatment methodologies for CKD
Emergence of alternative therapies for metabolic acidosis
Potential for larger pharmaceutical companies to enter the market with more resources
High debt-to-equity ratio indicating significant leverage and financial risk
Negative operating cash flow impacting liquidity
moderate - The demand for healthcare products can be somewhat insulated from economic downturns, but overall healthcare spending is influenced by GDP growth and consumer spending.
Interest rates can affect Tricida's cost of capital for funding R&D and operations. Higher rates may increase financing costs, impacting cash flow and valuation multiples.
minimal - The company is not heavily reliant on external financing given its current zero revenue status, but high debt levels could pose risks if cash flow does not improve.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has exhibited significant volatility, with a 1-year return of -98.8% reflecting market uncertainty.
